Clinical Trials
24 trials177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
OHSU Knight Cancer Institute
ReLUTH
Institut du Cancer de Montpellier - Val d'Aurelle
LUPARPED
Fundación de investigación HM
Comparing Retreatment of 177Lu-DOTATATE PRRT Versus the Usual Treatment in Patients With Metastatic Unresectable Gastroenteropancreatic Neuroendocrine Tumors, NET RETREAT Trial
National Cancer Institute (NCI)
Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells
National Cancer Institute (NCI)
Lu-177-DOTATATE (Lutathera) in Combination With Olaparib in Inoperable Gastroenteropancreatico Neuroendocrine Tumors (GEP-NET)
National Institutes of Health Clinical Center (CC)
Using Novel Imaging to More Safely Treat Neuroendocrine Tumors
University of Wisconsin, Madison
Testing Lutetium Lu 177 Dotatate in Patients With Somatostatin Receptor Positive Advanced Bronchial Neuroendocrine Tumors
National Cancer Institute (NCI)
Testing the Addition of Sunitinib Malate to Lutetium Lu 177 Dotatate (Lutathera) in Pancreatic Neuroendocrine Tumors
National Cancer Institute (NCI)
Lu-177-DOTATATE (Lutathera) in Therapy of Inoperable Pheochromocytoma/ Paraganglioma
National Institutes of Health Clinical Center (CC)
Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
Mayo Clinic
iPRRT
Weill Medical College of Cornell University
Lutathera for Treatment of Recurrent or Progressive High-Grade CNS Tumors
Nationwide Children's Hospital
Combination External Radiation and PRRT for Large GI Neuroendocrine Tumors.
Emory University
Study to Test the Combination of Fulvestrant With Lu-DOTATATE for Advanced Pancreatic Neuroendocrine Tumors
University of Chicago
Surgical Debulking Prior to Peptide Receptor Radionuclide Therapy in Well Differentiated Gastroenteropancreatic Neuroendocrine Tumors
Vanderbilt-Ingram Cancer Center
LANTana
Imperial College London
LUMEN-1
European Organisation for Research and Treatment of Cancer - EORTC
Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery
Stanford University
RIALTO
Grupo Espanol de Tumores Neuroendocrinos
A Trial to Assess the Safety and Effectiveness of Lutetium-177 Octreotate Therapy in Neuroendocrine Tumours
AHS Cancer Control Alberta
LUMOD-ID
University of Iowa
LuDO-N
Karolinska University Hospital
DOBATOC
University of Aarhus